They showed in three different tumor models (MC38, A20 and EG7) that PD-L1 expression in tumor cells was dispensable for the effective response to the anti-PD-L1 therapy, while its expression in myeloid cells was crucial since PD-L1 expression on these cells actively participated to the suppression of T cell function. This evidence concerns the gene CD274 and neoplasm.